Panic Disorder is an anxiety disorder characterized by repeated, unpredictable, panic attacks which are experienced without the presence of a known fear of stressor.

Current medicinal treatment options include serotonin and norepinephrine reuptake inhibitors (SSRI/SNRIs) and benzodiazepines (BDZs). However new treatments that safely improve the symptoms of a panic disorder without the adverse effects or serious toxicities of these current medications, are desperately needed.

Momentum are conducting a clinical research study investigating a new potential treatment that targets the CNS physiological stress system aiming to normalise the stress response for people with panic disorder. The study aims to demonstrate that the investigational treatment is safer and more tolerable and reduces panic disorder symptoms compared to currently available medicinal treatments.

You may be eligible to participate if you:

• Are 18-65 years old with panic disorder.
• Have had a minimum of one full, unexpected panic attack in the week prior to screening for the study.
• Are medically stable on any current medication for at least 3 months.

Please note it is important that study participants remain on any of their current psychiatric medications through the length of the study.

Other inclusion and exclusion criteria apply.

The study has a duration of approximately 15-weeks and involves 6 visits to the clinic and 9 video calls with research staff.

Eligible participants will be compensated for time and travel-related costs.{insert relevant details}

The study is being conducted at the following locations:

• Momentum Darlinghurst Sydney

Please contact us on 1300 190 841 or info@momentumclinicalresearch.com.au for further information or follow the link below.